Skip to main content

Culturing Drug-Resistant Tumors

Improved methods to grow patients’ tumor cells in a dish offer opportunities to find durable therapies.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

FLICKR, ANNE WESTON, LRI, CROK. WELLCOME IMAGESCancers can become resistant to drugs that once seemed like they could cure a person of the disease. In the unstopping march toward personalized medicine, researchers managed to culture drug-resistant lung tumor cells to screen them for sensitivity to various therapies, finding new and sometimes surprising drug candidates.

“It’s a substantial step,” Jeffrey Engelman of Massachusetts General Hospital Cancer Center told Time. “Because before we just had the genetic information but we wouldn’t have the cells alive so that we could test what types of therapies might work.”

Engelman and his colleagues published their study in Science last week (November 13). They succeeded in growing cells taken from 20 patients’ tumors. Nature News pointed out that, in many cases, the drug screens turned up unexpected candidates. In half of the tumors, for example, a drug that inhibits a protein called SRC managed to shrink tumor growth in vitro. “There were no genetic results that would have pointed to that combination,” Engelman told Nature News.

Engelman’s method has yet to face a clinical challenge; ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Related Topics

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Miltenyi
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays